Quantcast

Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company

September 27, 2010

LYON, France, September 27, 2010 /PRNewswire-FirstCall/ — Sanofi
Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and
NYSE: SNY) announced today that it has signed a binding agreement for the
acquisition of VaxDesign, a privately held U.S. biotechnology company, based
in Orlando, Florida, that develops, manufactures and markets in vitro models
of the human immune system.

VaxDesign is the developer of the Modular IMmune In-vitro Construct
(MIMIC(R)) technology that melds immunology with engineering to find
solutions to complex biological problems. The system is built to capture
genetic and environmental diversity and based on data generated in a
surrogate human immune system, provides earlier selection of the optimal
product candidate as opposed to using animal models before studies in human
clinical trials. MIMIC(R) will be relevant in the assessment of the value of
Sanofi Pasteur’s vaccine candidates, providing a key “filter” in the
preclinical stage for a “go/no go” decision-making process before Phase I
human clinical trials.

Under the terms of the agreement, Sanofi Pasteur will make an upfront
payment of US $55 million upon closing of the transaction and an additional
US $5 million upon realization of a certain development step. The closing of
the transaction is expected to occur by the end of 2010, subject to customary
conditions precedent.

“MIMIC(R) is the most-advanced platform in the field,” declared Michel
DeWilde
, Ph.D., Senior Vice President, Research and Development, Sanofi
Pasteur. “With this novel model for understanding mechanisms of action, the
probability of clinical success increases and the time to market should
decrease. MIMIC(R) successfully reproduced our own clinical data and is
adaptable for the evaluation of multiple diseases and corresponding patient
populations. This platform will provide a significant competitive advantage
in the development of vaccines.”

“We are excited and appreciative to be part of the Sanofi Pasteur legacy
of innovation,” said VaxDesign’s President & CEO William Warren, Ph.D. “The
acquisition enables us to leave an imprint on public health through concrete
applications of the immune system in a test tube.”

About VaxDesign

VaxDesign, is a privately held U.S. biotechnology company, based in
Orlando, Florida, that develops, manufactures, and markets in vitro models of
the human immune system. Its Modular IMmune In vitro Construct (MIMIC(R))
technology melds immunology with engineering to find elegant solutions to
complex biological problems. The MIMIC(R) system was initially developed for
the Rapid Vaccine Assessment Program of the U.S. Defense Advanced Research
Projects Agency (DARPA) and has since been funded by several other U.S.
federal agencies, such as the Defense Threat Reduction Agency, Biomedical
Advanced Research and Development Authority, Army Chemical Biological Medical
Systems (CBMS), and National Institute of Standards and Technology (NIST).

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY). For more information, please visit: www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than 1.6 billion doses of vaccine in 2009, making it possible to
immunize more than 500 million people across the globe. A world leader in the
vaccine industry, Sanofi Pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The company’s heritage, to create
vaccines that protect life, dates back more than a century. Sanofi Pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR 1 million in research and development. For more
information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential and statements regarding future performance.
Forward-looking statements are generally identified by the words “expects,”
“anticipates,” “believes,” “intends,” “estimates,” “plans” and similar
expressions. Although sanofi-aventis’ management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the
FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could
affect the availability or commercial potential of such products candidates,
the absence of guarantee that the products candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives, the Group’s ability to benefit from external growth
opportunities as well as those discussed or identified in the public filings
with the SEC and the AMF made by sanofi-aventis, including those listed under
“Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended
December 31, 2009. Other than as required by applicable law, sanofi-aventis
does not undertake any obligation to update or revise any forward-looking
information or statements.

http://www.sanofipasteur.com

http://www.sanofipasteur.us

SOURCE Sanofi Pasteur


Source: newswire



comments powered by Disqus